Literature DB >> 23842874

[Vitreomacular Traction Syndrome (VMTS)].

M M Maier1, N Feucht, S Burzer, C P Lohmann.   

Abstract

In vitreomacular traction syndrome (VMTS) an anomalous posterior vitreous detachment (APVD) with persistant symptomatic vitreoretinal adhesion is seen. The adhesion leads to a thickened macula, to macular oedema and a reduction of BCVA. Modern imaging techniques like spectral domain OCT (SD-OCT) allow a detailed imaging of the retinal microstructure and the vitreoretinal interface. Vitreomacular adhesions and their effect on the retina can be visualised. Until now, the treatment option for VMTS was and is vitreoretinal surgery. In studies pharmacological vitreolysis has shown a therapeutic effect in patients with symptomatic adhesion and traction. The results of these studies represent an important step towards a pharmacological treatment of VMTS. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2013        PMID: 23842874     DOI: 10.1055/s-0032-1328641

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  6 in total

1.  [Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole. First clinical experiences].

Authors:  M Maier; S Abraham; C Frank; N Feucht; C P Lohmann
Journal:  Ophthalmologe       Date:  2015-12       Impact factor: 1.059

2.  [Importance of morphological and functional diagnostics of the vitreoretinal interface].

Authors:  W J Mayer; R G Schumann; A Kampik; C Haritoglou
Journal:  Ophthalmologe       Date:  2015-01       Impact factor: 1.059

3.  [Optical coherence tomography in eyes with senile retinoschisis : SD-OCT versus ultrasound examinations and assessment of the vitreoretinal interface].

Authors:  A Bringewatt; S Burzer; N Feucht; M Maier
Journal:  Ophthalmologe       Date:  2018-04       Impact factor: 1.059

4.  [Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy].

Authors:  M Maier; S Abraham; C Frank; C P Lohmann; N Feucht
Journal:  Ophthalmologe       Date:  2017-02       Impact factor: 1.059

Review 5.  Ocriplasmin: who is the best candidate?

Authors:  Claudia M Prospero Ponce; William Stevenson; Rachel Gelman; Daniel R Agarwal; John B Christoforidis
Journal:  Clin Ophthalmol       Date:  2016-03-17

6.  Factors Associated with the Clinical Course of Vitreomacular Traction.

Authors:  Petros Petrou; Evangelia Chalkiadaki; Marie-Helene Errera; Sidath Liyanage; Louisa Wickham; Evangelia Papakonstantinou; Aristotelis Karamaounas; Menelaos Kanakis; Ilias Georgalas; Stylianos Kandarakis; David Charteris
Journal:  J Ophthalmol       Date:  2020-12-21       Impact factor: 1.909

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.